Chinese General Practice ›› 2021, Vol. 24 ›› Issue (36): 4587-4592.DOI: 10.12114/j.issn.1007-9572.2021.02.058
Special Issue: 内分泌代谢性疾病最新文章合集; 中医最新文章合集; 消化系统疾病最新文章合集
• Monographic Research • Previous Articles Next Articles
Published:
2021-12-20
Online:
2021-12-20
基金资助:
FAN Yaofu,CAO Lin,SUN Hongping,XU Juan,BAO Weiping,CHU Xiaoqiu. Clinical Study of Gegen Qinlian Decoction in Type 2 Diabetes with Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2021, 24(36): 4587-4592.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.058
组别 | 例数 | 性别(男/女) | 年龄(岁) | 病程(年) | 体质量(kg/m2) | 高血压〔n(%)〕 |
---|---|---|---|---|---|---|
对照组 | 45 | 30/15 | 38.0±7.8 | 3.54±1.36 | 27.9±3.6 | 8(17.8) |
观察组 | 45 | 28/17 | 37.4±8.1 | 3.37±1.40 | 28.2±3.7 | 6(13.3) |
t(χ2)值 | 0.194a | 0.380 | 0.584 | -0.348 | 0.338a | |
P值 | 0.660 | 0.705 | 0.561 | 0.728 | 0.561 |
Table 1 Comparison of general information between control and observation groups
组别 | 例数 | 性别(男/女) | 年龄(岁) | 病程(年) | 体质量(kg/m2) | 高血压〔n(%)〕 |
---|---|---|---|---|---|---|
对照组 | 45 | 30/15 | 38.0±7.8 | 3.54±1.36 | 27.9±3.6 | 8(17.8) |
观察组 | 45 | 28/17 | 37.4±8.1 | 3.37±1.40 | 28.2±3.7 | 6(13.3) |
t(χ2)值 | 0.194a | 0.380 | 0.584 | -0.348 | 0.338a | |
P值 | 0.660 | 0.705 | 0.561 | 0.728 | 0.561 |
组别 | 例数 | 治疗前 | 治疗后 | t配对值 | P值 |
---|---|---|---|---|---|
对照组 | 45 | 6.47±2.12 | 4.33±1.32 | 5.748 | <0.001 |
观察组 | 45 | 6.69±2.25 | 3.07±1.09 | 9.713 | <0.001 |
t值 | 0.477 | 4.937 | |||
P值 | 0.634 | <0.001 |
Table 2 Comparison of mean scores of TCM syndromes in two groups before and after treatment
组别 | 例数 | 治疗前 | 治疗后 | t配对值 | P值 |
---|---|---|---|---|---|
对照组 | 45 | 6.47±2.12 | 4.33±1.32 | 5.748 | <0.001 |
观察组 | 45 | 6.69±2.25 | 3.07±1.09 | 9.713 | <0.001 |
t值 | 0.477 | 4.937 | |||
P值 | 0.634 | <0.001 |
组别 | 例数 | FPG(mmol/L) | 2 hPG(mmol/L) | ||||||
---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | ||
对照组 | 45 | 7.3±1.3 | 5.9±1.3 | 5.294 | <0.001 | 14.0±2.3 | 9.9±2.0 | 9.076 | <0.001 |
观察组 | 45 | 7.4±1.3 | 5.3±1.2 | 8.191 | <0.001 | 13.9±2.4 | 7.5±1.8 | 14.228 | <0.001 |
t值 | 0.450 | 2.203 | 0.287 | 5.813 | |||||
P值 | 0.654 | 0.030 | 0.775 | <0.001 |
Table 3 Comparison of mean levels of glycolipid metabolism indices in two groups before and after treatment
组别 | 例数 | FPG(mmol/L) | 2 hPG(mmol/L) | ||||||
---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | ||
对照组 | 45 | 7.3±1.3 | 5.9±1.3 | 5.294 | <0.001 | 14.0±2.3 | 9.9±2.0 | 9.076 | <0.001 |
观察组 | 45 | 7.4±1.3 | 5.3±1.2 | 8.191 | <0.001 | 13.9±2.4 | 7.5±1.8 | 14.228 | <0.001 |
t值 | 0.450 | 2.203 | 0.287 | 5.813 | |||||
P值 | 0.654 | 0.030 | 0.775 | <0.001 |
组别 | 例数 | ALT(U/L) | AST(mmol/L) | GGT(mmol/L) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | ||
对照组 | 45 | 74.65±18.14 | 43.02±9.33 | 10.402 | <0.001 | 62.26±9.38 | 42.16±6.70 | 11.697 | 0.002 | 98.38±15.16 | 61.72±10.64 | 13.278 | <0.001 |
观察组 | 45 | 78.17±15.50 | 34.91±8.39 | 15.552 | <0.001 | 59.37±8.45 | 34.57±8.91 | 13.548 | <0.001 | 94.12±17.62 | 47.75±10.93 | 15.002 | <0.001 |
t值 | 0.990 | 3.896 | 1.536 | 4.567 | 1.229 | 6.144 | |||||||
P值 | 0.325 | <0.001 | 0.128 | <0.001 | 0.222 | <0.001 |
Table 4 Comparison of mean levels of liver function markers in two groups before and after treatment
组别 | 例数 | ALT(U/L) | AST(mmol/L) | GGT(mmol/L) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | ||
对照组 | 45 | 74.65±18.14 | 43.02±9.33 | 10.402 | <0.001 | 62.26±9.38 | 42.16±6.70 | 11.697 | 0.002 | 98.38±15.16 | 61.72±10.64 | 13.278 | <0.001 |
观察组 | 45 | 78.17±15.50 | 34.91±8.39 | 15.552 | <0.001 | 59.37±8.45 | 34.57±8.91 | 13.548 | <0.001 | 94.12±17.62 | 47.75±10.93 | 15.002 | <0.001 |
t值 | 0.990 | 3.896 | 1.536 | 4.567 | 1.229 | 6.144 | |||||||
P值 | 0.325 | <0.001 | 0.128 | <0.001 | 0.222 | <0.001 |
组别 | 例数 | CD4+ T淋巴细胞(%) | CD8+ T淋巴细胞(%) | ||||||
---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | ||
对照组 | 45 | 30.54±2.26 | 36.92±1.53 | 15.682 | <0.001 | 35.46±3.66 | 31.39±2.84 | 5.894 | <0.001 |
观察组 | 45 | 31.15±2.36 | 43.53±2.12 | 26.178 | <0.001 | 35.81±3.13 | 27.64±3.02 | 12.601 | <0.001 |
t值 | 1.252 | 16.960 | 0.488 | 6.068 | |||||
P值 | 0.214 | <0.001 | 0.627 | <0.001 |
Table 5 Comparison of mean levels of immune function markers in two groups before and after treatment
组别 | 例数 | CD4+ T淋巴细胞(%) | CD8+ T淋巴细胞(%) | ||||||
---|---|---|---|---|---|---|---|---|---|
治疗前 | 治疗后 | t配对值 | P值 | 治疗前 | 治疗后 | t配对值 | P值 | ||
对照组 | 45 | 30.54±2.26 | 36.92±1.53 | 15.682 | <0.001 | 35.46±3.66 | 31.39±2.84 | 5.894 | <0.001 |
观察组 | 45 | 31.15±2.36 | 43.53±2.12 | 26.178 | <0.001 | 35.81±3.13 | 27.64±3.02 | 12.601 | <0.001 |
t值 | 1.252 | 16.960 | 0.488 | 6.068 | |||||
P值 | 0.214 | <0.001 | 0.627 | <0.001 |
组别 | 例数 | 治疗前 | 治疗后 | t配对值 | P值 |
---|---|---|---|---|---|
对照组 | 45 | 9.63±2.46 | 6.42±1.74 | 7.146 | <0.001 |
观察组 | 45 | 9.58±2.53 | 4.67±1.85 | 10.509 | <0.001 |
t值 | 0.095 | 4.147 | |||
P值 | 0.924 | <0.001 |
Table 6 Comparison of mean NAFLD fibrosis scores measured by color Doppler ultrasonography in two groups before and after treatment
组别 | 例数 | 治疗前 | 治疗后 | t配对值 | P值 |
---|---|---|---|---|---|
对照组 | 45 | 9.63±2.46 | 6.42±1.74 | 7.146 | <0.001 |
观察组 | 45 | 9.58±2.53 | 4.67±1.85 | 10.509 | <0.001 |
t值 | 0.095 | 4.147 | |||
P值 | 0.924 | <0.001 |
[1] | LI J, ZOU B, YEO Y H,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999—2019:a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.DOI:10.1016/s2468-1253(19)30039-1. |
[2] | RINELLA M E.Nonalcoholic fatty liver disease:a systematic review[J]. JAMA,2015,313(22):2263-2273.DOI:10.1001/jama.2015.5370. |
[3] | KIM H, LEE D S, AN T H,et al. Metabolic spectrum of liver failure in type 2 diabetes and obesity:from NAFLD to NASH to HCC[J]. Int J Mol Sci,2021,22(9):4495.DOI:10.3390/ijms22094495. |
[4] | HAZLEHURST J M, WOODS C, MARJOT T,et al. Non-alcoholic fatty liver disease and diabetes[J]. Metabolism,2016,65(8):1096-1108.DOI:10.1016/j.metabol.2016.01.001. |
[5] | LIM S, KIM J W, TARGHER G.Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease[J]. Trends Endocrinol Metab,2021,32(7):500-514.DOI:10.1016/j.tem.2021.04.008. |
[6] | BRIL F, CUSI K.Management of nonalcoholic fatty liver disease in patients with type 2 diabetes:a call to action[J]. Diabetes Care,2017,40(3):419-430.DOI:10.2337/dc16-1787. |
[7] | LEE C H, LUI D T W, LAM K S L.Adipocyte fatty acid-binding protein,cardiovascular diseases and mortality[J]. Front Immunol,2021,12:589206.DOI:10.3389/fimmu.2021.589206. |
[8] | 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志,2018,38(4):292-344.DOI:10.19538/j.nk2018040108. |
[9] | 隋淼,蒋小飞,范尧夫,等. 葛根芩连汤含药血清通过miR-146b/SIRT1信号通路改善HepG2细胞胰岛素抵抗的研究[J]. 中药材,2019,42(3):630-635.DOI:10.13863/j.issn1001-4454.2019.03.034. |
[10] | SUI M, CHEN G F, MAO X D,et al. Gegen Qinlian decoction ameliorates hepatic insulin resistance by silent information Regulator1 (SIRT1)-dependent deacetylation of forkhead box O1 (FOXO1)[J]. Med Sci Monit,2019,25:8544-8553.DOI:10.12659/MSM.919498. |
[11] | DAVIS T M E.Diabetes and metabolic dysfunction-associated fatty liver disease[J]. Metabolism,2021,123:154868.DOI:10.1016/j.metabol.2021.154868. |
[12] | KHNEIZER G, RIZVI S, GAWRIEH S.Non-alcoholic fatty liver disease and diabetes mellitus[J]. Adv Exp Med Biol,2021,1307:417-440.DOI:10.1007/5584_2020_532 |
[13] | 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志,2018,34(5):947-957. |
[14] | 李先进,王瑾茜,刘侃.体针配合葛根芩连汤治疗肥胖型糖尿病湿热困脾证的临床观察[J]. 辽宁中医杂志,2016,43(7):1475-1478.DOI:10.13192/j.issn.1000-1719.2016.07.044. |
[15] | International Diabetes Federation.IDF Diabetes Atlas,8th ed[EB/OL]. [2021-03-20]. . |
[16] | 王雨涵,高影.非酒精性脂肪性肝病并发2型糖尿病诊断和治疗的研究进展[J]. 吉林大学学报:医学版,2020,46(6):1324-1331.DOI:10.13481/j.1671-587x.20200634. |
[17] | YAMAZAKI H, TSUBOYA T, TSUJI K,et al. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes[J]. Diabetes Care,2015,38(9):1673-1679.DOI:10.2337/dc15-0140. |
[18] | 吴勇,吴应林,李瑞麟.褪黑素对2型糖尿病患者细胞免疫功能和感染的影响[J]. 安徽医学,2019,40(11):1212-1215. |
[19] | MA C, KESARWALA A H, EGGERT T,et al. NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis[J]. Nature,2016,531(7593):253-257.DOI:10.1038/nature16969. |
[20] | FERNÁNDEZ-DELGADO I, CALZADA-FRAILE D, SÁNCHEZ-MADRID F.Immune regulation by dendritic cell extracellular vesicles in cancer immunotherapy and vaccines[J]. Cancers,2020,12(12):3558.DOI:10.3390/cancers12123558. |
[21] | AKHTAR M, NIZAM N N, BASHER S R,et al. dmLT adjuvant enhances cytokine responses to T cell stimuli,whole cell vaccine antigens and lipopolysaccharide in both adults and infants[J]. Front Immunol,2021,12:654872.DOI:10.3389/fimmu.2021.654872. |
[22] | TANG T, SUI Y, LIAN M,et al. Pro-inflammatory activated Kupffer cells by lipids induce hepatic NKT cells deficiency through activation-induced cell death[J]. PLoS One,2013,8(12):e81949.DOI:10.1371/journal.pone.0081949. |
[23] | 李勤,倪青,石白,等. 2型糖尿病合并非酒精性脂肪性肝病中医药研究进展[J]. 中国中医药信息杂志,2019,26(8):141-144. |
[24] | 韩智慧,王亚玲,王淑美,等. 基于1H NMR代谢组学方法研究葛根芩连汤对IR大鼠模型血浆代谢组的影响[J]. 广东药学院学报,2015,31(6):786-790. |
[25] | LI Y C, WANG B Y, SHEN J D,et al. Berberine attenuates fructose-induced insulin resistance by stimulating the hepatic LKB1/AMPK/PGC1α pathway in mice[J]. Pharm Biol,2020,58(1):385-392.DOI:10.1080/13880209.2020.1756349. |
[26] | SONG M Y, WANG J H, EOM T,et al. Schisandra chinensis fruit modulates the gut microbiota composition in association with metabolic markers in obese women:a randomized,double-blind placebo-controlled study[J]. Nutr Res,2015,35(8):655-663.DOI:10.1016/j.nutres.2015.05.001. |
[27] | LAN X F, OLALEYE O E, LU J L,et al. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing Lianhua Qingwen capsule[J]. Acta Pharmacol Sin,2021.DOI:10.1038/s41401-021-00651-2. |
[28] | YANG Y M, SEO S Y, KIM T H,et al. Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B,which is reversed by licorice flavonoid[J]. Hepatology,2012,56(6):2209-2220.DOI:10.1002/hep.25912. |
[1] | YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314. |
[2] | LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012. |
[3] | YAO Junjie, SHANG Qiangqiang, WANG Yufeng, LI Jiahui, LIU Chang, PANG Tingting. Wearable Inertial Sensors-based Efficacy Evaluation of Comprehensive Traditional Chinese Medicine Therapy for Lumbar Disc Herniation Due to Qi-stagnation and Blood-stasis [J]. Chinese General Practice, 2023, 26(27): 3450-3455. |
[4] | LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372. |
[5] | LU Bin, XIANG Chong, YUAN Xuesong, CAI Gaojun, WEI Wenfeng, YAN Yongmin. Effectiveness, Safety and Satisfaction of Distal Transradial Artery Approach in Cerebral Angiography [J]. Chinese General Practice, 2023, 26(27): 3378-3382. |
[6] | KONG Dexian, XING Yuling, SUN Wenwen, ZHANG Zhimin, ZHOU Fei, MA Huijuan. Correlation between Estimated Glucose Disposal Rate and Metabolism-associated Fatty Liver Disease in Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(26): 3252-3258. |
[7] | GAO Zhe, DUAN Kaixin, LYU Xiuqin, MA Huijuan, ZHANG Zhimei, SONG Guangyao. Mechanism of Glucagon-like Peptide-1 Receptor Agonist Improving Liver Lipid Deposition in a Rat Model of Insulin Resistance Induced by High-fructose Diet [J]. Chinese General Practice, 2023, 26(21): 2639-2646. |
[8] | ZHANG Zhuoran, YU Changhe, AN Yi, HE Xin, GUO Yi, DENG Jinyan, LI Yue, HAN Deng, PI Shanshan, HE Junzhi, CHEN Yue, YE Yong'an, DU Hongbo. Quality Assessment and Recommendations of Clinical Guidelines and Consensuses on Non-alcoholic Fatty Liver Disease: a Comparative Study [J]. Chinese General Practice, 2023, 26(20): 2439-2446. |
[9] | GAO Yang, WANG Yunxia, GAO Chuanyu. Familial Hypercholesterolemia in 45-year-old and Younger Patients with Acute Coronary Syndrome: Clinical Characteristics and Influencing Factors of Blood Lipid Control Effect [J]. Chinese General Practice, 2023, 26(18): 2232-2237. |
[10] | YANG Bei, HAN Lin, WANG Yin, CHENG Kangyao. Effectiveness of Continuous Subcutaneous Insulin Injection in Type 2 Diabetes in Older Adults: a Meta-analysis and Trial Sequential Analysis [J]. Chinese General Practice, 2023, 26(15): 1892-1901. |
[11] | LIU Chuanfen, LI Zheng, WU Manyan, CUI Yuxia, SONG Jing, ZHANG Chunying, CHEN Hong. Analysis of Serum Lipid Level and Drug Use in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(11): 1325-1329. |
[12] | FEI Jingwen, LIN Huize, ZHANG Pingping, LIU Lanping, WANG Xiang, SHEN Jianghong, ZHU Kexin, YANG Tao, YU Jinna. Motion Style Acupuncture Can Effectively Improve the Effectiveness of Acute Nonspecific Low Back Pain: a Meta-analysis [J]. Chinese General Practice, 2023, 26(09): 1044-1052. |
[13] | QIAN Fangfang, CAI Zhensheng, GU Tian, LI Haoxiang, ZHAO Li, YANG Ling, DENG Xia, YUAN Guoyue. Relationship between Ectodysplasin A and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(08): 911-916. |
[14] | GUAN Ningxiao, YAO Zhuoya, LI Ye, LIU Ziwei, LIU Fangli. Non-invasive Brain Stimulation Techniques Can Effectively Relieve Post-stroke Fatigue: a Meta-analysis [J]. Chinese General Practice, 2023, 26(08): 1008-1014. |
[15] | FU Weiqiang, ZHOU Jianbo, WU Xiongjian, HUANG Caibin. Treatment Strategy of Nonalcoholic Fatty Liver Disease Targeting the Intestinal Microbiota [J]. Chinese General Practice, 2023, 26(06): 742-748. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||